Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Shire completes $2.4bn sale of oncology business to Servier
The franchise includes the global rights to ONCASPAR and ex-US and ex-Taiwan rights to ONIVYDE, as well as Oncology pipeline assets. David Lee, who was previously the head
The franchise includes the global rights to ONCASPAR and ex-US and ex-Taiwan rights to ONIVYDE, as well as Oncology pipeline assets. David Lee, who was previously the head
The FDA in its complete response letter issued to the company conveyed that the new drug application (NDA) for dasotraline could not be approved in its current form.
The Phase 2 study (B5161002), did not meet its primary efficacy endpoint, which was to demonstrate a difference in the mean change from baseline in 4 Stair Climb
KaNDy is focused on optimizing the potential of NT-814 as a non-hormonal treatment for common, chronic debilitating female sex-hormone associated conditions. The funding came from new US investor
The new facility, which will serve as the flagship location for ICS, will further strengthen the company’s already robust end-to-end, integrated solutions for improving access to specialty medication,
Under the terms of the agreement, Purdue will pay Assertio a total of $62 million in cash, with $30 million in cash paid on August 28, 2018 and
The approved indications are for the treatment of pediatric and young adult patients up to 25 years of age with B-cell acute lymphoblastic leukemia (ALL) that is refractory,
CogniCann is one of MXC’s medical cannabis pharmaceutical products with a THC:CBD ratio specifically formulated to treat key Dementia symptoms and enhance specific cognitive functions. The approval was
HAE is a rare, genetic and potentially life-threatening disorder that can result in recurrent attacks of edema (swelling) in various parts of the body. Hereditary Angioedema Association president
The agreement will not include South Korea where JWP will retain its exclusivity over the JW1601 drug, which was developed by one of its affiliates – C&C Research